Navicyte provides a drug delivery platform that directs immune‑targeted therapeutics to improve efficacy, safety, and development flexibility.
Funding
Funding not disclosed
Founders
Product
Problem
Drug developers face challenges delivering immune-modulating therapeutics efficiently, often requiring high doses that increase off‑target exposure and limit safety, while existing delivery methods lack flexibility for diverse molecular formats.
Solution
Navicyte offers a drug delivery platform that directs immune‑targeted therapeutics to specific sites, substantially expanding the therapeutic index—by more than 500‑fold in pre‑clinical models. The technology reduces required doses by up to 85%, lowering systemic exposure and improving safety profiles. It supports a broad range of payloads, including small molecules, proteins, nucleic acids, vaccines, and adjuvants, providing developers with flexible formulation options. Release kinetics are tunable, enabling precise control over drug exposure timing. The platform is designed for compatibility with FDA‑GMP manufacturing processes, facilitating integration into existing development pipelines.
Target Audience
Primary customers are pharmaceutical and biotech companies developing immune‑modulating drugs that require enhanced efficacy, safety, and formulation flexibility.
Features
- Immune‑targeted delivery mechanism that concentrates therapeutics at intended sites
- Demonstrated >500‑fold expansion of therapeutic index in animal studies
- Dose reduction capability of up to 85% to minimize off‑target effects
- Compatibility with multiple therapeutic modalities: small molecules, proteins, nucleic acids, vaccines, and adjuvants
- Tunable release kinetics for customized dosing schedules
- Designed for FDA‑GMP compliant manufacturing and scale‑up